News ArchivesRead News
Rave drug sparks hope for treating Parkinson’s
Wednesday June 20, 2012
bioscholar - Rave culture’s illicit drug ‘ecstasy’ can help develop drugs that curb involuntary movements in Parkinson’s disease, says a study.
A team led by a medicinal chemist at The University of Western Australia (UWA) studied the possibility. Matthew Piggott, associate professor, said Parkinson’s patients have a great deal of difficulty moving without medication.
The drug, levodopa, restores their movement but, over time, side-effects often develop. These include a reduction in therapeutic duration and jerky, involuntary movements known as dyskinesia.
“Dyskinesia is often confused as a symptom of Parkinson’s disease, when in fact it is a side-effect of the treatment,” Piggott was quoted as saying in the Journal of the Federation of American Societies for Experimental Biology.
“For some time now we’ve known that the drug most commonly sold as ‘ecstasy’, methylenedioxymethamphetamine (MDMA), ameliorates the side-effects of levodopa therapy. But MDMA has no therapeutic potential because it makes users ‘high’,” said Piggot, according to a university statement.
“Although controversial, there is also evidence that MDMA may be neurotoxic, or at least responsible for long-term, deleterious changes in brain chemistry,” Piggot said.
The team of UWA scientists, collaborating with Parkinson’s disease experts in Toronto, has now demonstrated that it is possible to de-link the beneficial effects of MDMA from its undesirable attributes. The feat was achieved through the creation of MDMA analogues – new compounds with a similar chemical structure to MDMA.
“The best compound, which we call UWA-101, is even more effective than MDMA at enhancing the quality of levodopa therapy,” said Piggot.
If translated to a medicine, this would mean that Parkinson’s patients could take their medication less frequently and get a better quality result from it,” Piggot added.
Disclaimer: Bioscholar is not intended to provide medical advice, diagnosis or treatment. The articles are based on peer reviewed research, and discoveries/products mentioned in the articles may not be approved by the regulatory bodies.
Recent NewsJan 2 - January 2, 2018 News Update
Dec 26 - December 26, 2017 News Update
Dec 19 - December 19, 2017 News Update
Dec 8 - New technique scours the genome for genes that combat disease
Dec 8 - Restless sleep may be an early sign of Parkinson's, dementia
Dec 1 - Defects in cell's 'waste disposal system' linked to Parkinson's
Dec 1 - Dual virtual reality/treadmill exercises promote brain plasticity in Parkinson's patients
Nov 17 - 'Moving Day' participant is not letting young-onset Parkinson's disease stop him
Nov 17 - Focused ultrasound shows promise for treating Parkinson's tremor
Nov 17 - New research to target air pollution as a potential trigger for Parkinson’s
Nov 17 - This device will let you feel what it's like to suffer from Parkinson's
Nov 10 - How does Parkinson's disease influence depression?
Nov 10 - House votes to repeal ObamaCare's Medicare cost-cutting board
Nov 10 - Microsoft shows off watch that quiets Parkinson's tremors
Nov 3 - Utah group battling Parkinson's disease with boxing
Nov 3 - UVA-LED STUDY EXAMINES POTENTIAL OF SOUND WAVES TO MANAGE PARKINSON’S DISEASE
Oct 27 - Herbicide's link to Parkinson's disease
Oct 27 - NTU Singapore, KAIST scientists discover new mechanism that causes Parkinsonian symptoms
Oct 27 - 70,000 Washingtonians face higher insurance costs after Trump order, officials say
Oct 18 - Brain disconnections may contribute to Parkinson's hallucinations